8-K: Dermata Therapeutics Regains Compliance with Stockholders Equity Requirement but Faces Delisting Threat Due to Minimum Bid Price

Dermata Therapeutics has regained compliance with Nasdaq's stockholders equity requirement but is now facing potential delisting due to non-compliance with the minimum bid price rule.

Summary

• Dermata Therapeutics, Inc. received notification from Nasdaq on May 14, 2025, that it had regained compliance with the minimum stockholders equity requirement.
• However, on the same day, the company received notice that it is not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
• Due to a prior reverse stock split within the last year, Dermata's securities are subject to delisting and will be suspended on May 23, 2025, unless the company requests a hearing before the Nasdaq Hearings Panel by May 21, 2025.
• Dermata plans to request a hearing to stay the suspension and delisting action.
• There is no guarantee that Dermata's compliance plan will be accepted or that the company will regain compliance and maintain its Nasdaq listing.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the potential delisting from Nasdaq, despite regaining compliance with the stockholders equity requirement. The uncertainty surrounding the hearing outcome further contributes to the negative outlook.

Positives

• Dermata Therapeutics has regained compliance with the Nasdaq Stockholders Equity Requirement.

Negatives

• Dermata Therapeutics is not in compliance with the $1.00 Minimum Bid Price requirement.
• The company's securities are subject to delisting from the Nasdaq Capital Market.

Risks

• There is no assurance that Dermata's compliance plan will be accepted by Nasdaq.
• The company may not be able to regain compliance with the Minimum Bid Price requirement.
• Failure to regain compliance could result in delisting from the Nasdaq Capital Market.

Future Outlook

The company intends to request a hearing before the Nasdaq Hearings Panel to appeal the potential delisting. The outcome of this hearing and the company's ability to regain compliance with the minimum bid price requirement are uncertain.

Industry Context

Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, particularly regarding minimum bid price requirements. Reverse stock splits are a common but often viewed negatively by investors, and are often used to regain compliance.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the value of their investment.
• Employees may experience uncertainty due to the potential delisting.
• The company's reputation and ability to raise capital could be negatively affected.

Next Steps

• Dermata Therapeutics will request a hearing before the Nasdaq Hearings Panel by May 21, 2025.
• The company will present a plan to regain compliance with the Minimum Bid Price requirement.

Key Dates

Keywords

delisting, minimum bid price, compliance, Nasdaq, Dermata Therapeutics, stockholders equity